DESTINY-Breast11: Clinically Relevant Adverse Events

Tune in to explore the clinically relevant safety profile of T-DXd–based neoadjuvant therapy in high-risk HER2+ early breast cancer from DESTINY-Breast11.

ReachMD Healthcare Image
Media formats available
  • Completing the pre-test is required to access this content.
    Pre-Survey
    Completing the pre-survey is required to access this content.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free